Dr Reddy's Gets Brazil Approval For Generic Ozempic Diabetes Drug

Indian pharmaceutical company Dr Reddy's Laboratories has secured approval from Brazil's National Health Surveillance Agency to market a generic version of Novo Nordisk's diabetes medication Ozempic. The agency, known as ANVISA, granted clearance for the semaglutide injection aimed at adults with type 2 diabetes whose blood sugar levels remain uncontrolled.

The medicine is meant to be used in conjunction with dietary changes and physical activity. This approval marks a significant step in Dr Reddy's strategy to expand its international footprint, with generic semaglutide considered a potential growth driver in multiple markets. The Brazilian regulatory body had previously denied the drug's application in April due to non-compliance with all requirements.

Upon receiving the latest approval, Dr Reddy's is now authorized to sell the injectable treatment in pre-filled pens containing 2 mg and 4 mg doses of semaglutide. Brazil is a crucial market for diabetes treatments, housing approximately 16.6 million adults aged 20 to 79 with the disease, ranking the country sixth globally in terms of affected adults.

Semaglutide is the key ingredient in Ozempic and Wegovy, which is used for weight management. Dr Reddy's has identified the generic version of semaglutide as an important avenue for future business growth. The company is set to reintroduce generic semaglutide in Canada during the current quarter following a previous recall due to an impurity found in the active pharmaceutical ingredient.

Dr Reddy's also aims to introduce semaglutide products to other Latin American and African markets in the coming months, as part of its broader strategy to bolster its presence in international pharmaceutical markets. The Brazilian approval bolsters Dr Reddy's position in the emerging market for semaglutide-based diabetes treatments, though subsequent launches will depend on compliance with relevant regulatory standards.